Renier J Brentjens

List of Publications by Year
in descending order

108 papers	17,470 citations	61857 43 h-index	46693 89 g-index
110 all docs	110 docs citations	110 times ranked	15464 citing authors

#	Article	IF	Citations
1	Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia. Science Translational Medicine, 2014, 6, 224ra25.	5.8	2,069
2	Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia. New England Journal of Medicine, 2018, 378, 449-459.	13.9	1,951
3	CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia. Science Translational Medicine, 2013, 5, 177ra38.	5.8	1,748
4	Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood, 2011, 118, 4817-4828.	0.6	1,135
5	The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nature Reviews Clinical Oncology, 2016, 13, 273-290.	12.5	909
6	Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nature Reviews Clinical Oncology, 2020, 17, 147-167.	12.5	786
7	Toxicity and management in CAR T-cell therapy. Molecular Therapy - Oncolytics, 2016, 3, 16011.	2.0	686
8	Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia. Cancer Discovery, 2018, 8, 958-971.	7.7	594
9	Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nature Medicine, 2003, 9, 279-286.	15.2	586
10	Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. Nature Biotechnology, 2018, 36, 847-856.	9.4	564
11	Driving CAR T-cells forward. Nature Reviews Clinical Oncology, 2016, 13, 370-383.	12.5	492
12	Genetically Targeted T Cells Eradicate Systemic Acute Lymphoblastic Leukemia Xenografts. Clinical Cancer Research, 2007, 13, 5426-5435.	3.2	398
13	CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date. Blood, 2016, 127, 3312-3320.	0.6	346
14	IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors<i>in vivo</i>. OncoImmunology, 2015, 4, e994446.	2.1	336
15	Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment. Scientific Reports, 2017, 7, 10541.	1.6	288
16	Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System. Cell Reports, 2018, 23, 2130-2141.	2.9	233
17	GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. Science Translational Medicine, 2019, 11, .	5.8	229
18	Novel immunotherapies in lymphoid malignancies. Nature Reviews Clinical Oncology, 2016, 13, 25-40.	12.5	224

#	Article	IF	Citations
19	A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Antiâ€"PD-1 Agent Pembrolizumab. Cancer Discovery, 2021, 11, 2748-2763.	7.7	222
20	A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16ecto directed chimeric antigen receptors for recurrent ovarian cancer. Journal of Translational Medicine, 2015, 13, 102.	1.8	221
21	Loss of the HVEM Tumor Suppressor in Lymphoma and Restoration by Modified CAR-T Cells. Cell, 2016, 167, 405-418.e13.	13.5	204
22	Enhancing Antitumor Efficacy of Chimeric Antigen Receptor T Cells Through Constitutive CD40L Expression. Molecular Therapy, 2015, 23, 769-778.	3.7	195
23	Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL. Blood, 2019, 134, 2361-2368.	0.6	190
24	Armored CAR T-cells: utilizing cytokines and pro-inflammatory ligands to enhance CAR T-cell anti-tumour efficacy. Biochemical Society Transactions, 2016, 44, 412-418.	1.6	182
25	Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance. , 2018, 6, 137.		182
26	CD40 Ligand-Modified Chimeric Antigen Receptor T Cells Enhance Antitumor Function by Eliciting an Endogenous Antitumor Response. Cancer Cell, 2019, 35, 473-488.e6.	7.7	159
27	CAR Tâ€cell therapy: Full speed ahead. Hematological Oncology, 2019, 37, 95-100.	0.8	131
28	Sensitive in vivo imaging of T cells using a membrane-bound Gaussia princeps luciferase. Nature Medicine, 2009, 15, 338-344.	15.2	120
29	Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy. Nature Medicine, 2022, 28, 713-723.	15.2	117
30	Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escapeâ€"Driven Relapse in Multiple Myeloma. Blood Cancer Discovery, 2020, 1, 146-154.	2.6	114
31	Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion. Nature Reviews Clinical Oncology, 2022, 19, 342-355.	12.5	113
32	High day 28 ST2 levels predict for acute graft-versus-host disease and transplant-related mortality after cord blood transplantation. Blood, 2015, 125, 199-205.	0.6	109
33	Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management. Blood Advances, 2020, 4, 676-686.	2.5	101
34	Development and Evaluation of a Human Single Chain Variable Fragment (scFv) Derived Bcma Targeted CAR T Cell Vector Leads to a High Objective Response Rate in Patients with Advanced MM. Blood, 2017, 130, 742-742.	0.6	92
35	Development of CAR T cells designed to improve antitumor efficacy and safety. , 2017, 178, 83-91.		90
36	Tumor derived UBR5 promotes ovarian cancer growth and metastasis through inducing immunosuppressive macrophages. Nature Communications, 2020, 11, 6298.	5.8	82

#	Article	IF	Citations
37	Review: Current clinical applications of chimeric antigen receptor (CAR) modified T cells. Cytotherapy, 2016, 18, 1393-1409.	0.3	79
38	Development and Evaluation of an Optimal Human Single-Chain Variable Fragment-Derived BCMA-Targeted CAR T Cell Vector. Molecular Therapy, 2018, 26, 1447-1456.	3.7	77
39	Overcoming Antigen Escape with CAR T-cell Therapy. Cancer Discovery, 2015, 5, 1238-1240.	7.7	69
40	Autologous CD19-Targeted CAR T Cells in Patients with Residual CLL following Initial Purine Analog-Based Therapy. Molecular Therapy, 2018, 26, 1896-1905.	3.7	65
41	Building a CAR Garage: Preparing for the Delivery of Commercial CAR T Cell Products at Memorial Sloan Kettering Cancer Center. Biology of Blood and Marrow Transplantation, 2018, 24, 1135-1141.	2.0	60
42	BCMA-Targeted CAR T-cell Therapy plus Radiotherapy for the Treatment of Refractory Myeloma Reveals Potential Synergy. Cancer Immunology Research, 2019, 7, 1047-1053.	1.6	59
43	Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells. Blood Advances, 2021, 5, 3397-3406.	2.5	59
44	Early experience using salvage radiotherapy for relapsed/refractory nonâ€Hodgkin lymphomas after CD19 chimericÂantigen receptor (CAR)ÂT cell therapy. British Journal of Haematology, 2020, 190, 45-51.	1.2	51
45	Modeling anti-CD19 CAR T cell therapy in humanized mice with human immunity and autologous leukemia. EBioMedicine, 2019, 39, 173-181.	2.7	47
46	CD19 CAR Therapy for Acute Lymphoblastic Leukemia. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , e360-e363.	1.8	45
47	Adoptive T-Cell Therapy for Solid Tumors. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 193-204.	1.8	44
48	Medical management of side effects related to CAR T cell therapy in hematologic malignancies. Expert Review of Hematology, 2016, 9, 511-513.	1.0	43
49	Frontiers in cancer immunotherapyâ€"a symposium report. Annals of the New York Academy of Sciences, 2021, 1489, 30-47.	1.8	39
50	Engineering CAR-T cells to activate small-molecule drugs in situ. Nature Chemical Biology, 2022, 18, 216-225.	3.9	39
51	Implications of Minimal Residual Disease Negative Complete Remission (MRD-CR) and Allogeneic Stem Cell Transplant on Safety and Clinical Outcome of CD19-Targeted 19-28z CAR Modified T Cells in Adult Patients with Relapsed, Refractory B-Cell ALL. Blood, 2015, 126, 682-682.	0.6	37
52	Tumors evading CARsâ€"the chase is on. Nature Medicine, 2018, 24, 1492-1493.	15.2	32
53	IL-18 Secreting CAR T Cells Enhance Cell Persistence, Induce Prolonged B Cell Aplasia and Eradicate CD19+ Tumor Cells without Need for Prior Conditioning. Blood, 2016, 128, 816-816.	0.6	28
54	CAR therapy for hematological cancers: can success seen in the treatment of B-cell acute lymphoblastic leukemia be applied to other hematological malignancies?. Immunotherapy, 2015, 7, 545-561.	1.0	26

#	Article	IF	Citations
55	Human cytomegalovirus expands a CD8 ⁺ T cell population with loss of <i>BCL11B</i> expression and gain of NK cell identity. Science Immunology, 2021, 6, eabe6968.	5.6	25
56	Screening Clinical Cell Products for Replication Competent Retrovirus: The National Gene Vector Biorepository Experience. Molecular Therapy - Methods and Clinical Development, 2018, 10, 371-378.	1.8	24
57	Impact of bridging chemotherapy on clinical outcome of CD19 CAR T therapy in adult acute lymphoblastic leukemia. Leukemia, 2021, 35, 3268-3271.	3.3	21
58	CD103+ cDC1 and endogenous CD8+ T cells are necessary for improved CD40L-overexpressing CAR T cell antitumor function. Nature Communications, 2020, 11, 6171.	5.8	20
59	Bispecific T-Cell Engaging Antibodies Against MUC16 Demonstrate Efficacy Against Ovarian Cancer in Monotherapy and in Combination With PD-1 and VEGF Inhibition. Frontiers in Immunology, 2021, 12, 663379.	2.2	20
60	Emerging Role of CAR T Cells in Non-Hodgkin's Lymphoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 1429-1437.	2.3	18
61	CD19-directed chimeric antigen receptor T cell therapy in WaldenstrÃ¶m macroglobulinemia: a preclinical model and initial clinical experience. , 2022, 10, e004128.		18
62	Targeted Cellular Micropharmacies: Cells Engineered for Localized Drug Delivery. Cancers, 2020, 12, 2175.	1.7	17
63	Depletion of high-content CD14+ cells from apheresis products is critical for successful transduction and expansion of CAR TÂcells during large-scale cGMP manufacturing. Molecular Therapy - Methods and Clinical Development, 2021, 22, 377-387.	1.8	17
64	Excessive Costimulation Leads to Dysfunction of Adoptively Transferred T Cells. Cancer Immunology Research, 2020, 8, 732-742.	1.6	16
65	Application of CAR T cells for the treatment of solid tumors. Progress in Molecular Biology and Translational Science, 2019, 164, 293-327.	0.9	15
66	Acute myeloid leukemia arising from a donor derived premalignant hematopoietic clone: A possible mechanism for the origin of leukemia in donor cells. Leukemia Research Reports, 2014, 3, 38-41.	0.2	14
67	Intestinal Microbiota Composition Prior to CAR T Cell Infusion Correlates with Efficacy and Toxicity. Blood, 2018, 132, 3492-3492.	0.6	13
68	Low toxicity and favorable overall survival in relapsed/refractory B-ALL following CAR T cells and CD34-selected T-cell depleted allogeneic hematopoietic cell transplant. Bone Marrow Transplantation, 2020, 55, 2160-2169.	1.3	11
69	At the Bench: Chimeric antigen receptor (CAR) T cell therapy for the treatment of B cell malignancies. Journal of Leukocyte Biology, 2016, 100, 1255-1264.	1.5	10
70	Hiding in plain sight: immune escape in the era of targeted T-cell-based immunotherapies. Nature Reviews Clinical Oncology, 2017, 14, 333-334.	12.5	10
71	CARs of the future. American Journal of Hematology, 2019, 94, S55-S58.	2.0	10
72	Enhancing CAR T cell efficacy: the next step toward a clinical revolution?. Expert Review of Hematology, 2020, 13, 533-543.	1.0	10

#	Article	IF	Citations
73	Multi-Center Clinical Trial of CAR T Cells in Pediatric/Young Adult Patients with Relapsed B-Cell ALL. Blood, 2015, 126, 2533-2533.	0.6	10
74	CD33-Directed Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Acute Myeloid Leukemia (AML). Blood, 2016, 128, 2825-2825.	0.6	9
75	Multipurposing CARs: Same engine, different vehicles. Molecular Therapy, 2022, 30, 1381-1395.	3.7	9
76	Concurrent therapy of chronic lymphocytic leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia utilizing CD19-targeted CAR T-cells. Leukemia and Lymphoma, 2018, 59, 1717-1721.	0.6	6
77	Impact of the Conditioning Chemotherapy On Outcomes in Adoptive T Cell Therapy: Results From a Phase I Clinical Trial of Autologous CD19-Targeted T Cells for Patients with Relapsed CLL. Blood, 2012, 120, 1797-1797.	0.6	6
78	CD19 Targeted Allogeneic EBV-Specific T Cells for the Treatment of Relapsed ALL in Pediatric Patients Post HSCT. Blood, 2012, 120, 353-353.	0.6	6
79	Cellular therapies in acute lymphoblastic leukemia. Current Opinion in Molecular Therapeutics, 2009, 11, 375-82.	2.8	6
80	The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia. , 2020, 8, e000810.		5
81	Safe and Effective Re-Induction Of Complete Remissions In Adults With Relapsed B-ALL Using 19-28z CAR CD19-Targeted T Cell Therapy. Blood, 2013, 122, 69-69.	0.6	5
82	Phase I Trial Of Autologous CD19-Targeted CAR-Modified T Cells As Consolidation After Purine Analog-Based First-Line Therapy In Patients With Previously Untreated CLL. Blood, 2013, 122, 874-874.	0.6	5
83	Novel approaches to immunotherapy for B-cell malignancies. Current Oncology Reports, 2004, 6, 339-347.	1.8	4
84	Enhancing CAR T Cell Anti-Tumor Efficacy through Secreted Single Chain Variable Fragment (scFv) Immune Checkpoint Blockade. Blood, 2017, 130, 842-842.	0.6	3
85	Novel approaches to immunotherapy for B-cell malignancies. Psychophysiology, 2005, 4, 64-72.	1.1	2
86	Dawn of chimeric antigen receptor T cell therapy in non-Hodgkin Lymphoma. Advances in Cell and Gene Therapy, 2018, 1, e23.	0.6	1
87	CAR T cells, immunologic and cellular therapies in hematologic malignancies. Best Practice and Research in Clinical Haematology, 2018, 31, 115-116.	0.7	1
88	Virus Specific T-Lymphocytes Genetically Modified to Target the CD19 Antigen Eradicates Systemic Lymphoma In Mice. Blood, 2010, 116, 2092-2092.	0.6	1
89	Constitutive Expression of CD40L by CAR-Modified Tumor Targeted T Cells Enhances Anti-Tumor Efficacy Both in Vitro and in Vivo. Blood, 2012, 120, 4120-4120.	0.6	1
90	Chronic Myeloid Leukemia After Adjuvant Treatment For Breast Cancer: Is It Therapy Related?. Blood, 2013, 122, 2740-2740.	0.6	1

#	Article	IF	Citations
91	Discovery and Validation of a Novel Class of Small Molecule Inhibitors of the CDC7 Kinase: Modulation of Tumor Cell Growth in Vitro and In Vivo.. Blood, 2009, 114, 3771-3771.	0.6	1
92	Aerobic Glycolysis Predicts Outcome in Early Chronic Lymphocytic Leukemia.. Blood, 2012, 120, 2482-2482.	0.6	1
93	Molecular Remission and B Cell Aplasia Induced in a First Cohort of Adults with Relapsed B-ALL Treated with 19â€“28z CAR-Targeted T Cells. Blood, 2012, 120, 3566-3566.	0.6	1
94	CAR T Cells for Mantle Cell Lymphoma: Is it Time to Reshuffle the Deck?. Cancer Cell, 2020, 37, 761-763.	7.7	0
95	Chimeric Antigen Receptorâ€“Modified Immune Effector Cell Therapies. Cancer Journal (Sudbury, Mass), 2021, 27, 90-91.	1.0	0
96	Characteristic Proinflammatory Serum Cytokine Profiles In Patients with B-Cell Chronic Lymphocytic Leukemia. Blood, 2010, 116, 3595-3595.	0.6	0
97	CD19 Targeted Cord Blood Derived T Cells for Cancer Immunotherapy.. Blood, 2010, 116, 3767-3767.	0.6	0
98	Tumor Specific T Cells Modified to Secrete IL-12 Eradicate Systemic Tumors in the Absence of Prior Toxic Chemotherapy Conditioning Regimens. Blood, 2011, 118, 3120-3120.	0.6	0
99	Elevated Mitochondrial Membrane Potential in CLL Cells Is Associated with a more aggressive Natural History. Blood, 2011, 118, 1765-1765.	0.6	0
100	In Vivo comparison of 3 Suicide Gene-Prodrug Combinations in a Mouse Graft-Versus-Host-Disease Model. Blood, 2011, 118, 3121-3121.	0.6	0
101	Influence of National Comprehensive Cancer Network (NCCN) Guidelines on Clinical Practice in Patients with Chronic Myelogenous Leukemia (CML) Treated At a Single Academic Medical Center. Blood, 2011, 118, 4433-4433.	0.6	0
102	Enhanced Antitumor Efficacy of MUC-16 Targeted T Cells Further Modified to Constitutively Express the IL-12 Cytokine in a Syngeneic Model of Ovarian Cancer,. Blood, 2011, 118, 4176-4176.	0.6	0
103	Conditioning Intensity and T Cell Dose Determine Efficacy of CD19-Targeted T Cell-Mediated Tumor Eradication in an Immunocompetent Mouse Model of B-ALL.. Blood, 2012, 120, 2613-2613.	0.6	0
104	Highly Sensitive Bioluminescence in Vivo Imaging Enables Individualized Preclinical Treatment Trials On Patients ALL Tumor Cells Growing in Mice.. Blood, 2012, 120, 2602-2602.	0.6	0
105	Micafungin Versus Posaconazole Anti-Fungal Prophylaxis in Adult Patients with Acute Leukemia Undergoing Induction Chemotherapy. Blood, 2012, 120, 3556-3556.	0.6	0
106	Abstract Title Submitted by Hollie Pegram to the 2012 ASH Annual Meeting: Expansion and Modification of Umbilical Cord Blood T Cells with a Chimeric Antigen Receptor and IL-12. Blood, 2012, 120, 1907-1907.	0.6	0
107	CAR T Cells in Acute Lymphoblastic Leukemia. , 2015, 12, .		0
108	The Development of a qPCR Assay for the Evaluation of the Dendritic Cell Chimeric Antigen Receptor Transcriptome. Blood, 2016, 128, 5895-5895.	0.6	0